Search results for "CTLA-4 Antigen"

showing 10 items of 35 documents

Polymorphisms in genes involved in T-cell co-stimulation are associated with blood pressure in women.

2019

In recent years, conclusive data have emerged on a relationship between immune system, especially the T-cell, and blood pressure (BP). The objective of the present study was to determine the association between BP and four polymorphisms in CD80, CD86, CD28 and CTLA4 genes that code for key proteins in the T-cell co-stimulation process, in a female cohort. To that end, an association study in a cohort of 934 women over 40 years old from two hospitals was done. Raw data showed a significant association between the SNP rs1129055 of CD86 gene and BP. Analyzing this association against inheritance patterns, higher SBP (p  0.000) and DBP (p = 0.005) values were observed in AA than in GG/GA genoty…

0301 basic medicineAdultT cellT-LymphocytesPhysiologychemical and pharmacologic phenomenaBlood PressureBiologyPolymorphism Single Nucleotide03 medical and health sciences0302 clinical medicineImmune systemCD28 AntigensGeneticsmedicineInheritance PatternsSNPHumansCTLA-4 AntigenGenetic Predisposition to DiseaseGeneCD86hemic and immune systemsGeneral MedicineMiddle Aged030104 developmental biologyBlood pressuremedicine.anatomical_structure030220 oncology & carcinogenesisCohortB7-1 AntigenFemaleB7-2 AntigenGene
researchProduct

Integrative analysis of key candidate genes and signaling pathways in autoimmune thyroid dysfunction related to anti-CTLA-4 therapy by bioinformatics

2020

Summary Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), the first immune checkpoint to be targeted clinically, has provided an effective treatment option for various malignancies. However, the clinical advantages associated with CTLA-4 inhibitors can be offset by the potentially severe immune-related adverse events (IRAEs), including autoimmune thyroid dysfunction. To investigate the candidate genes and signaling pathways involving in autoimmune thyroid dysfunction related to anti-CTLA-4 therapy, integrated differentially expressed genes (DEGs) were extracted from the intersection of genes from Gene Expression Omnibus (GEO) datasets and text mining. The functional enrichment was perfo…

0301 basic medicineCandidate geneCD74Signaling pathway.FCGR2BDifferentially expressed geneBiologyBioinformaticsHyperthyroidismAutoimmune Diseases03 medical and health sciencesMice0302 clinical medicineHypothyroidismmedicineAnimalsHumansPharmacology (medical)CTLA-4 AntigenProtein Interaction MapsKEGGGeneImmune Checkpoint InhibitorsPharmacologyPreclinical StudiesSignaling pathwayCancerComputational Biologymedicine.diseaseImmune checkpointGene Expression Regulation Neoplastic030104 developmental biologyGene OntologyAutoimmune thyroid dysfunctionOncologyCTLA-4030220 oncology & carcinogenesisDifferentially expressed genesCTLA-4BiomarkersImmune checkpoint blockadeSignal Transduction
researchProduct

Thymus-derived regulatory T cells are positively selected on natural self-antigen through cognate interactions of high functional avidity

2016

Regulatory T (Treg) cells expressing Foxp3 transcripton factor are essential for immune homeostasis. They arise in the thymus as a separate lineage from conventional CD4+Foxp3- T (Tconv) cells. Here, we show that the thymic development of Treg cells depends on the expression of their endogenous cognate self-antigen. The formation of these cells was impaired in mice lacking this self-antigen, while Tconv cell development was not negatively affected. Thymus-derived Treg cells were selected by self-antigens in a specific manner, while autoreactive Tconv cells were produced through degenerate recognition of distinct antigens. These distinct modes of development were associated with the expressi…

0301 basic medicineCell typeCancer ResearchEncephalomyelitis Autoimmune ExperimentalMultiple Sclerosis[SDV]Life Sciences [q-bio]ImmunologyReceptors Antigen T-CellEndogenyT-Cell Antigen Receptor Specificitychemical and pharmacologic phenomenaThymus GlandBiologymedicine.disease_causeAutoantigensT-Lymphocytes RegulatoryAutoimmunity03 medical and health sciencesMice0302 clinical medicineAntigenT-Lymphocyte SubsetsmedicineImmunology and AllergyAnimalsHumansAvidityCTLA-4 AntigenReceptorClonal Selection Antigen-MediatedCells CulturedMice KnockoutCell growthFOXP3Forkhead Transcription Factorshemic and immune systemsPeptide Fragments[SDV] Life Sciences [q-bio]Mice Inbred C57BL030104 developmental biologyInfectious DiseasesImmunologyMyelin-Oligodendrocyte Glycoprotein030215 immunology
researchProduct

Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection

2018

The identification of reliable predictive biomarkers of efficacy or resistance to immune-oncology (I–O) agents is a major issue for translational research and clinical practice. However, along with PDL1 and molecular features other clinical, radiological and laboratory factors can be considered for the selection of those patients who would not be the best candidate for immune-checkpoint inhibitors (ICPIs). We examined these factors, emerging from the results of currently available studies in non-small cell lung cancer (NSCLC), aiming to provide a useful and manageable tool which can help Oncologists in their everyday clinical practice. A thorough patient evaluation and close clinical monito…

0301 basic medicineOncologymedicine.medical_specialtyLung NeoplasmsImmune-checkpoint inhibitorSettore MED/06 - Oncologia MedicaImmune-checkpoint inhibitorsBiomarkers; Immune-checkpoint inhibitors; Immune-oncology; Non-small cell lung cancer; Predictive factors; Antibodies Monoclonal; B7-H1 Antigen; Biomarkers; CTLA-4 Antigen; Carcinoma Non-Small-Cell Lung; Humans; Immunotherapy; Lung Neoplasms; Patient Selection; Hematology; OncologyAntibodiesB7-H1 Antigen03 medical and health sciences0302 clinical medicineNon-small cell lung cancerCarcinoma Non-Small-Cell LungInternal medicineMonoclonalmedicineHumansCTLA-4 AntigenNeutrophil to lymphocyte ratioNon-Small-Cell LungLung cancerHepatitisPerformance statusbusiness.industryPatient SelectionCarcinomaInterstitial lung diseaseAntibodies MonoclonalBronchiolitis obliterans organizing pneumoniaBiomarkerHematologymedicine.diseaseBiomarkers; Immune-checkpoint inhibitors; Immune-oncology; Non-small cell lung cancer; Predictive factors; Hematology; OncologyClinical trial030104 developmental biologyOncology030220 oncology & carcinogenesisImmunotherapyPredictive factorbusinessBiomarkersImmune-oncologyPredictive factorsProgressive diseaseCritical Reviews in Oncology/Hematology
researchProduct

Can Immunogenic Chemotherapies Relieve Cancer Cell Resistance to Immune Checkpoint Inhibitors?

2019

The unprecedented clinical activity of checkpoint blockade in several types of cancers has formally demonstrated that anti-tumor immune responses are crucial in cancer therapy. Durable responses seen in patients treated with immune checkpoint inhibitors (ICI) show that they can trigger the establishment of long-lasting immunologic memory. This beneficial outcome is however achieved for a limited number of patients. In addition, late relapses are emerging suggesting the development of acquired resistances that compromise the anticancer efficacy of ICI. How can this be prevented through combination therapies? We here review the functions of immune checkpoints, the successes of ICI in treating…

0301 basic medicineOrganoplatinum CompoundsImmune checkpoint inhibitorsmedicine.medical_treatmentProgrammed Cell Death 1 ReceptorLeucovorinReviewLymphocyte ActivationchemotherapyimmunomodulationB7-H1 AntigenMice0302 clinical medicineAntineoplastic Agents ImmunologicalcheckpointT-Lymphocyte SubsetsNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsTumor MicroenvironmentImmunology and AllergyCTLA-4 AntigenMolecular Targeted TherapyClinical Trials as TopicLymphokinesDrug Synergism3. Good healthNeoplasm ProteinsFluorouracillcsh:Immunologic diseases. AllergyImmunologyCancer therapyT cells03 medical and health sciencesImmune systemmedicineAnimalsHumanscancerIn patientChemotherapybusiness.industryCancermedicine.diseaseIpilimumabBlockade030104 developmental biologyDrug Resistance NeoplasmCancer cellCancer researchlcsh:RC581-607business030215 immunologyFrontiers in immunology
researchProduct

Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanoma

2016

CTLA-4 and PD-1 are potential targets for tumor-induced downregulation of lymphocytic immune responses. Immune checkpoint-modifying monoclonal antibodies oppose these effects, inducing T cell-mediated immune responses to various tumors including melanoma. Both anti-CTLA-4 and anti-PD-1 antibodies modify the interaction between tumor, antigen-presenting cells, and T lymphocytes. With respect to overall survival, clinical studies have shown a major benefit for the anti-CTLA-4 antibody ipilimumab as well as the two anti-PD-1 antibodies nivolumab and pembrolizumab. Following approval of ipilimumab in 2011, the latter two achieved market authorization in the summer of 2015. Immune responses thus…

0301 basic medicineSkin NeoplasmsDrug-Related Side Effects and Adverse Reactionsmedicine.drug_classMedizinAntineoplastic AgentsIpilimumabDermatologyPembrolizumabMonoclonal antibody03 medical and health sciences0302 clinical medicineImmune systemmedicineHumansCTLA-4 AntigenMelanomabiologybusiness.industryMelanomaAntibodies Monoclonalmedicine.diseaseIpilimumabImmune checkpoint030104 developmental biology030220 oncology & carcinogenesisImmunologybiology.proteinNivolumabAntibodybusinessmedicine.drugJDDG: Journal der Deutschen Dermatologischen Gesellschaft
researchProduct

Combined immunotherapy: CTLA-4 blockade potentiates anti-tumor response induced by transcutaneous immunization.

2017

Abstract Background The epidermal application of the Toll Like Receptor 7 agonist imiquimod and a T-cell peptide epitope (transcutaneous immunization, TCI) mediates systemic peptide-specific cytotoxic T-cell (CTL) responses and leads to tumor protection in a prophylactic tumor setting. However, it does not accomplish memory formation or permanent defiance of tumors in a therapeutic set-up. As a distinct immunologic approach, CTLA-4 blockade augments systemic immune responses and has shown long-lasting effects in preclinical experiments as well as in clinical trials. Objective The study investigates the vaccination capacity of TCI in combination with the checkpoint inhibitor CTLA-4 in matter…

0301 basic medicineSkin NeoplasmsOvalbuminmedicine.medical_treatmentMelanoma Experimentalchemical and pharmacologic phenomenaDermatologyBiochemistryT-Lymphocytes RegulatoryEpitope03 medical and health sciencesMice0302 clinical medicineImmune systemAntineoplastic Agents ImmunologicalAdjuvants ImmunologicmedicineCytotoxic T cellAnimalsHumansCTLA-4 AntigenMolecular BiologyImiquimodMembrane Glycoproteinsbusiness.industryMelanomahemic and immune systemsDrug SynergismTLR7Immunotherapymedicine.diseaseFlow CytometryXenograft Model Antitumor AssaysPeptide FragmentsMice Inbred C57BLCTL*030104 developmental biologyToll-Like Receptor 7CTLA-4030220 oncology & carcinogenesisImmunologyAminoquinolinesImmunotherapybusinessImmunologic MemoryT-Lymphocytes CytotoxicJournal of dermatological science
researchProduct

Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of…

2020

BackgroundImmune checkpoint inhibition (ICI) is an essential treatment option in melanoma. Its outcome may be improved by a preceding radiation of metastases. This study aimed to investigate the impact of a preceding radiotherapy on the clinical outcome of ICI treatment.MethodsThis multicenter retrospective cohort study included patients who received anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) or anti-programmed cell death protein 1 (PD-1) ICI with or without preceding radiotherapy for unresectable metastatic melanoma. ICI therapy outcome was measured as best overall response (BOR), progression-free (PFS) and overall survival (OS). Response and survival analyses were adjusted …

AdultMale0301 basic medicineOncologyCancer Researchmedicine.medical_specialtySkin NeoplasmsMetastatic melanoma2435medicine.medical_treatmentProgrammed Cell Death 1 ReceptorImmunologyMedizin03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansImmunology and AllergyCTLA-4 Antigen1506Immune Checkpoint InhibitorsMelanomaradiotherapyRC254-282Survival analysisRetrospective StudiesClinical/Translational Cancer ImmunotherapyPharmacologybusiness.industryMelanomaConfoundingNeoplasms. Tumors. Oncology. Including cancer and carcinogensRetrospective cohort studyChemoradiotherapyMiddle Agedmedicine.diseaseProgression-Free SurvivalImmune checkpointRadiation therapy030104 developmental biologyOncology030220 oncology & carcinogenesisRelative riskMolecular MedicineFemalebusinessJournal for ImmunoTherapy of Cancer
researchProduct

PTPN22 and CTLA-4 Polymorphisms Are Associated With Polyglandular Autoimmunity

2017

Context Single nucleotide polymorphisms (SNPs) of various genes increase susceptibility to monoglandular autoimmunity. Data on autoimmune polyglandular syndromes (APSs) are scarce. Objective Evaluate potential associations of eight SNPs with APSs. Setting Academic referral endocrine clinic. Patients A total of 543 patients with APS and monoglandular autoimmunity and controls. Intervention The SNP protein tyrosine phosphatase nonreceptor type 22 (PTPN22) rs2476601 (+1858); cytotoxic T-lymphocyte‒associated antigen 4 (CTLA-4) rs3087243 (CT60) and rs231775 (AG49); vitamin D receptor (VDR) rs1544410 (Bsm I), rs7975232 (Apa I), rs731236 (Taq I); tumor necrosis factor α rs1800630 (-863); and inte…

AdultMale0301 basic medicinemedicine.medical_specialtyGenotypeEndocrinology Diabetes and MetabolismGraves' diseaseClinical Biochemistry030209 endocrinology & metabolismSingle-nucleotide polymorphismPolymorphism Single NucleotideBiochemistryCalcitriol receptorPTPN22Young Adult03 medical and health sciences0302 clinical medicineEndocrinologyGene FrequencyInternal medicinemedicineHumansCTLA-4 AntigenGenetic Predisposition to DiseasePolyendocrinopathies AutoimmuneAllele frequencyGenetic Association Studiesbusiness.industryBiochemistry (medical)HaplotypeCase-control studyProtein Tyrosine Phosphatase Non-Receptor Type 22Odds ratioMiddle Agedmedicine.disease030104 developmental biologyEndocrinologyCase-Control StudiesFemalebusinessThe Journal of Clinical Endocrinology & Metabolism
researchProduct

Association of T-cell regulatory gene polymorphisms with oral squamous cell carcinoma

2010

Costimulatory molecules have complementary effects on T-cell activation and their balance may control the development of oral cancer. The aim of this study was to determine the relevance of cytotoxic T-lymphocyte antigen 4 (CTLA-4), CD28 and inducible costimulator (ICOS) polymorphisms in oral squamous cell carcinoma (OSCC). Genotyping for CTLA-4 (-1661 A/G and +49 A/G), CD28 (0 C/G and +3160 G/T) and ICOS (+637 A/C and +1599 C/T) was performed in the 83 patients with OSCC, compared to the 40 unrelated healthy volunteers as controls. The genotype CTLA-4 -1661 was significantly different between the patient group and the control group. The allele CTLA-4 -1661 G was significantly found more fr…

AdultMaleCancer ResearchT cellchemical and pharmacologic phenomenaLymphocyte ActivationT-Lymphocytes RegulatoryAntigenAntigens CDGenotypemedicineHumansCytotoxic T cellCTLA-4 AntigenGenetic Predisposition to DiseaseProspective StudiesAgedAged 80 and overMouth neoplasmPolymorphism Geneticbusiness.industryCD28hemic and immune systemsT lymphocyteMiddle AgedMolecular biologystomatognathic diseasesmedicine.anatomical_structureOncologyCTLA-4Case-Control StudiesImmunologyCarcinoma Squamous CellFemaleMouth NeoplasmsOral SurgerybusinessT-Lymphocytes CytotoxicOral Oncology
researchProduct